Current status of targeted therapy in metastatic transitional cell carcinoma of the bladder

Seminars in Oncology

Volumn 39, Issue 5, 2012, Pages 608-614

  Sadeghi, Sarmad ^a   Garcia, Jorge A ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; BEVACIZUMAB; CANCER VACCINE; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; DOXORUBICIN; ERLOTINIB; GEFITINIB; GEMCITABINE; LAPATINIB; METHOTREXATE; PACLITAXEL; PAZOPANIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; VANDETANIB; VASCULOTROPIN; VINBLASTINE;

ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; BLADDER METASTASIS; CANCER CHEMOTHERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CANCER THERAPY; CHROMOSOME ABERRATION; DEEP VEIN THROMBOSIS; DRUG SAFETY; DRUG TARGETING; HUMAN; LUNG EMBOLISM; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; SIGNAL TRANSDUCTION; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT RESPONSE;

CARCINOMA, TRANSITIONAL CELL; HUMANS; MOLECULAR TARGETED THERAPY; URINARY BLADDER NEOPLASMS;

EID: 84866987831     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2012.08.004     Document Type: Article

References (72)

1. R. Siegel, E. Ward, O. Brawley, A. Jemal Cancer statistics, 2011 CA Cancer J Clin 61 2011 212 236
2. J.A. Garcia, R. Dreicer Systemic chemotherapy for advanced bladder cancer: update and controversies J Clin Oncol 24 2006 5545 5551
3. X.R. Wu Urothelial tumorigenesis: a tale of divergent pathways Nat Rev Cancer 5 2005 713 725
4. A. Pich, L. Chiusa, A. Formiconi, D. Galliano, P. Bortolin, R. Navone Biologic differences between noninvasive papillary urothelial neoplasms of low malignant potential and low-grade (grade 1) papillary carcinomas of the bladder Am J Surg Pathol 25 2001 1528 1533
5. C. Billerey, D. Chopin, M.H. Aubriot-Lorton Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors Am J Pathol 158 2001 1955 1959
6. B.W. van Rhijn, I. Lurkin, F. Radvanyi, W.J. Kirkels, T.H. van der Kwast, E.C. Zwarthoff The fibroblast growth factor receptor 3 (FGFR3) mutation is a strong indicator of superficial bladder cancer with low recurrence rate Cancer Res 61 2001 1265 1268
7. J.F. Coleman, D.E. Hansel Utility of diagnostic and prognostic markers in urothelial carcinoma of the bladder Adv Anat Pathol 16 2009 67 78
8. E.P. Reddy, R.K. Reynolds, E. Santos, M. Barbacid A point mutation is responsible for the acquisition of transforming properties by the T24 human bladder carcinoma oncogene Nature 300 1982 149 152
9. D. Zhu, D. Xing, X. Shen, J. Liu A method to quantitatively detect H-ras point mutation based on electrochemiluminescence Biochem Biophys Res Commun 324 2004 964 969
10. N. Buyru, H. Tigli, F. Ozcan, N. Dalay Ras oncogene mutations in urine sediments of patients with bladder cancer J Biochem Mol Biol 36 4 Jul 31 2003 399 402
11. Z.T. Zhang, J. Pak, H.Y. Huang Role of Ha-ras activation in superficial papillary pathway of urothelial tumor formation Oncogene 20 2001 1973 1980
12. B. Czerniak, G.L. Cohen, P. Etkind Concurrent mutations of coding and regulatory sequences of the Ha-ras gene in urinary bladder carcinomas Hum Pathol 23 1992 1199 1204
13. D.W. Ye, J.F. Zheng, S.X. Qian, Y.J. Ma Correlation between the expression of oncogenes ras and c-erbB-2 and the biological behavior of bladder tumors Urol Res 21 1993 39 43
14. D. Cappellen, C. De Oliveira, D. Ricol Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas Nat Genet 23 1999 18 20
15. B.W. van Rhijn, R. Montironi, E.C. Zwarthoff, A.C. Jobsis, T.H. van der Kwast Frequent FGFR3 mutations in urothelial papilloma J Pathol 198 2002 245 251
16. A.A. Bakkar, H. Wallerand, F. Radvanyi FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder Cancer Res 63 2003 8108 8112
17. K.C. Hart, S.C. Robertson, M.Y. Kanemitsu, A.N. Meyer, J.A. Tynan, D.J. Donoghue Transformation and Stat activation by derivatives of FGFR1, FGFR3, and FGFR4 Oncogene 19 2000 3309 3320
18. P. Lipponen, M. Eskelinen Expression of epidermal growth factor receptor in bladder cancer as related to established prognostic factors, oncoprotein (c-erbB-2, p53) expression and long-term prognosis Br J Cancer 69 1994 1120 1125
19. C.L. Coogan, C.R. Estrada, S. Kapur, K.J. Bloom HER-2/neu protein overexpression and gene amplification in human transitional cell carcinoma of the bladder Urology 63 2004 786 790
20. A.A. Memon, B.S. Sorensen, P. Melgard, L. Fokdal, T. Thykjaer, E. Nexo Expression of HER3, HER4 and their ligand heregulin-4 is associated with better survival in bladder cancer patients Br J Cancer 91 2004 2034 2041
21. R. Stoehr, S. Zietz, M. Burger Deletions of chromosomes 9 and 8p in histologically normal urothelium of patients with bladder cancer Eur Urol 47 2005 58 63
22. C.H. Spruck 3rd, P.F. Ohneseit, M. Gonzalez-Zulueta Two molecular pathways to transitional cell carcinoma of the bladder Cancer Res 54 1994 784 788
23. M.A. Knowles, M.E. Shaw, A.J. Proctor Deletion mapping of chromosome 8 in cancers of the urinary bladder using restriction fragment length polymorphisms and microsatellite polymorphisms Oncogene 8 1993 1357 1364
24. R. Natrajan, J. Louhelainen, S. Williams, J. Laye, M.A. Knowles High-resolution deletion mapping of 15q13.2-q21.1 in transitional cell carcinoma of the bladder Cancer Res 63 2003 7657 7662
25. Z. Feng, W. Hu, W.N. Rom, F.A. Beland, M.S. Tang 4-aminobiphenyl is a major etiological agent of human bladder cancer: evidence from its DNA binding spectrum in human p53 gene Carcinogenesis 23 2002 1721 1727
26. J. Piette, H. Neel, V. Marechal Mdm2: keeping p53 under control Oncogene 15 1997 1001 1010
27. P. Cairns, A.J. Proctor, M.A. Knowles Loss of heterozygosity at the RB locus is frequent and correlates with muscle invasion in bladder carcinoma Oncogene 6 1991 2305 2309
28. S.F. Shariat, H. Tokunaga, J. Zhou p53, p21, pRB, and p16 expression predict clinical outcome in cystectomy with bladder cancer J Clin Oncol 22 2004 1014 1024
29. C. Cordon-Cardo, Z.F. Zhang, G. Dalbagni Cooperative effects of p53 and pRB alterations in primary superficial bladder tumors Cancer Res 57 1997 1217 1221
30. L.A. Ribeiro-Filho, J. Franks, M. Sasaki CpG hypermethylation of promoter region and inactivation of E-cadherin gene in human bladder cancer Mol Carcinog 34 2002 187 198
31. X. Garcia del Muro, A. Torregrosa, J. Munoz Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer Eur J Cancer 36 2000 357 362
32. K.M. Rieger-Christ, P. Lee, R. Zagha Novel expression of N-cadherin elicits in vitro bladder cell invasion via the Akt signaling pathway Oncogene 23 2004 4745 4753
33. S.C. Campbell, O.V. Volpert, M. Ivanovich, N.P. Bouck Molecular mediators of angiogenesis in bladder cancer Cancer Res 58 1998 1298 1304
34. G.D. Grossfeld, D.A. Ginsberg, J.P. Stein Thrombospondin-1 expression in bladder cancer: association with p53 alterations, tumor angiogenesis, and tumor progression J Natl Cancer Inst 89 1997 219 227
35. H. Kanayama Matrix metalloproteinases and bladder cancer J Med Invest 48 2001 31 43
36. J.I. Izawa, J.W. Slaton, D. Kedar Differential expression of progression-related genes in the evolution of superficial to invasive transitional cell carcinoma of the bladder Oncol Rep 8 2001 9 15
37. M. Komhoff, Y. Guan, H.W. Shappell Enhanced expression of cyclooxygenase-2 in high grade human transitional cell bladder carcinomas Am J Pathol 157 2000 29 35
38. A. Canoglu, C. Gogus, Y. Beduk, D. Orhan, O. Tulunay, S. Baltaci Microvessel density as a prognostic marker in bladder carcinoma: correlation with tumor grade, stage and prognosis Int Urol Nephrol 36 2004 401 405
39. W.D. Beecken, T. Engl, J. Hofmann, D. Jonas, R. Blaheta Clinical relevance of serum angiogenic activity in patients with transitional cell carcinoma of the bladder J Cell Mol Med 9 2005 655 661
40. K. Inoue, J.W. Slaton, D.W. Davis Treatment of human metastatic transitional cell carcinoma of the bladder in a murine model with the anti-vascular endothelial growth factor receptor monoclonal antibody DC101 and paclitaxel Clin Cancer Res 6 2000 2635 2643
41. K.A. Mohamedali, D. Kedar, P. Sweeney The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors Neoplasia 7 2005 912 920
42. L.G. Presta, H. Chen, S.J. O'Connor Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders Cancer Res 57 1997 4593 4599
43. N.M. Hahn, W.M. Stadler, R. Zon Mature results from Hoosier Oncology Group GU04-75 phase II trial of cisplatin (C), gemcitabine (G), and bevacizumab (B) as first-line chemotherapy for metastatic urothelial carcinoma (UC) ASCO Meeting Abstracts 28 15 suppl 2010 4541
44. T.W. Flaig, L.J. Su, C. McCoach Dual epidermal growth factor receptor and vascular endothelial growth factor receptor inhibition with vandetanib sensitizes bladder cancer cells to cisplatin in a dose- and sequence-dependent manner BJU Int 103 2009 1729 1737
45. D.F. Bajorin, P.M. Dodd, M. Mazumdar Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy J Clin Oncol 17 1999 3173 3181
46. H. von der Maase, S.W. Hansen, J.T. Roberts Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study J Clin Oncol 18 2000 3068 3077
47. J.F. Lyons, S. Wilhelm, B. Hibner, G. Bollag Discovery of a novel Raf kinase inhibitor Endocr Relat Cancer 8 2001 219 225
48. S.M. Wilhelm, C. Carter, L. Tang BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis Cancer Res 64 2004 7099 7109
49. S.S. Sridhar, E. Winquist, A. Eisen A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium Invest New Drugs 29 2011 1045 1049
50. R. Dreicer, H. Li, M. Stein Phase 2 trial of sorafenib in patients with advanced urothelial cancer: a trial of the Eastern Cooperative Oncology Group Cancer 115 2009 4090 4095
51. S. Krege, H. Rexer, F. vom Dorp Gemcitabine and cisplatin with or without sorafenib in urothelial carcinoma (AUO-AB 31/05) ASCO Meeting Abstracts 28 15 suppl 2010 4574
52. D.B. Mendel, A.D. Laird, X. Xin In vivo antitumor activity of SU11248, a novel TKI targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship Clin Cancer Res 9 2003 327 337
53. D.J. Gallagher, M.I. Milowsky, S.R. Gerst Phase II study of sunitinib in patients with metastatic urothelial cancer J Clin Oncol 28 2010 1373 1379
54. J. Bellmunt, J.L. Gonzalez-Larriba, C. Prior Phase II study of sunitinib as first-line treatment of urothelial cancer patients ineligible to receive cisplatin-based chemotherapy: baseline interleukin-8 and tumor contrast enhancement as potential predictive factors of activity Ann Oncol 22 2011 2646 2653
55. A. Necchi, N. Nicolai, C. Ortega Updated results of INT70/09 phase II study of pazopanib (PZP) monotherapy for patients with relapsed/refractory urothelial cancer (UC) ASCO Meeting Abstracts 29 15 suppl 2011 4618
56. T.K. Choueiri, U.N. Vaishampayan, E.Y. Yu A double-blind randomized trial of docetaxel plus vandetanib versus docetaxel plus placebo in platinum-pretreated advanced urothelial cancer ASCO Meeting Abstracts 29 7 suppl 2011 LBA239
57. W. Kassouf, P.C. Black, T. Tuziak Distinctive expression pattern of ErbB family receptors signifies an aggressive variant of bladder cancer J Urol 179 2008 353 358
58. K. Mellon, C. Wright, P. Kelly, C.H. Horne, D.E. Neal Long-term outcome related to epidermal growth factor receptor status in bladder cancer J Urol 153 1995 919 925
59. U. Lonn, S. Lonn, S. Friberg, B. Nilsson, C. Silfversward, B. Stenkvist Prognostic value of amplification of c-erb-B2 in bladder carcinoma Clin Cancer Res 1 1995 1189 1194
60. R.E. Jimenez, M. Hussain, F.J. Bianco Jr Her-2/neu overexpression in muscle-invasive urothelial carcinoma of the bladder: prognostic significance and comparative analysis in primary and metastatic tumors Clin Cancer Res 7 2001 2440 2447
61. M.H. Hussain, G.R. MacVicar, D.P. Petrylak Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial J Clin Oncol 25 2007 2218 2224
62. J. Bellmunt, H. von der Maase, G.M. Mead Randomized phase III study comparing paclitaxel/cisplatin/gemcitabine (PCG) and gemcitabine/cisplatin (GC) in patients with locally advanced (LA) or metastatic (M) urothelial cancer without prior systemic therapy; EORTC30987/Intergroup Study ASCO Meeting Abstracts 25 18 suppl 2007 LBA5030
63. P. Beuzeboc, E. Banu, E. Voog Trastuzumab (T) combined with standard chemotherapy in HER+ metastatic bladder cancer (BC) patients: interim safety results of a prospective randomized phase II study ASCO Meeting Abstracts 25 18 suppl 2007 15565
64. D.P. Petrylak, C.M. Tangen, P.J. Van Veldhuizen Jr Results of the Southwest Oncology Group phase II evaluation (study S0031) of ZD1839 for advanced transitional cell carcinoma of the urothelium BJU Int 105 2010 317 321
65. G.K. Philips, S. Halabi, B.L. Sanford, D. Bajorin, E.J. Small A phase II trial of cisplatin (C), gemcitabine (G) and gefitinib for advanced urothelial tract carcinoma: results of Cancer and Leukemia Group B (CALGB) 90102 Ann Oncol 20 2009 1074 1079
66. R.S. Pruthi, M. Nielsen, S. Heathcote A phase II trial of neoadjuvant erlotinib in patients with muscle-invasive bladder cancer undergoing radical cystectomy: clinical and pathological results BJU Int 106 2010 349 354
67. C. Wulfing, J.P. Machiels, D.J. Richel A single-arm, multicenter, open-label phase 2 study of lapatinib as the second-line treatment of patients with locally advanced or metastatic transitional cell carcinoma Cancer 115 2009 2881 2890
68. J. Kuball, S.F. Wen, J. Leissner Successful adenovirus-mediated wild-type p53 gene transfer in patients with bladder cancer by intravesical vector instillation J Clin Oncol 20 2002 957 965
69. M. Marchand, C.J. Punt, S. Aamdal Immunisation of metastatic cancer patients with MAGE-3 protein combined with adjuvant SBAS-2: a clinical report Eur J Cancer 39 2003 70 77
70. T. Nishiyama, M. Tachibana, Y. Horiguchi Immunotherapy of bladder cancer using autologous dendritic cells pulsed with human lymphocyte antigen-A24-specific MAGE-3 peptide Clin Cancer Res 7 2001 23 31
71. D.R. Leach, M.F. Krummel, J.P. Allison Enhancement of antitumor immunity by CTLA-4 blockade Science 271 1996 1734 1736
72. B.C. Carthon, J.D. Wolchok, J. Yuan Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial Clin Cancer Res 16 2010 2861 2871